Valrubicin: An Overview

What Is Valrubicin?

Valrubicin is a drug that is used primarily to treat non-invasive bladder cancer. Valrubicin is administered directly into the bladder, unlike most chemotherapy drugs, which are given into the bloodstream via IV (intravenous).

This enables the drug to directly attack cancer cells in their locations, but not the rest of the body. It is used as an intravesical therapy for bladder cancer as Bacillus Calmette–Guérin (BCG). Although BCG is mainly known as a tuberculosis vaccine, it is also used in the bladder to help treat certain bladder cancers.

With Valrubicin, doctors administer it by direct infusion into the bladder. This method makes this medicine different from other cancer medicines. Valrubicin drug came onto the market in the United States in 1999. The Food and Drug Administration (FDA), the primary drug regulatory agency in the United States, approved it in 1998.

For Patients

What Is Valrubicin Used For?

Valrubicin is primarily applied to non-invasive bladder cancer, i.e., the cancer has not metastasized outside of the bladder. The kind of cancer which is most likely to respond to Valrubicin is carcinoma in situ, in which the abnormal cells are confined to the bladder lining.

The majority of bladder cancer is initially treated by surgery to remove tumors. When surgery is not an option, physicians tend to resort to the BCG immunotherapy, which assists your immune system in combating the cancer.

When BCG is ineffective or inapplicable, Valrubicin can be considered a second option.

How Effective Is Valrubicin?

Valrubicin is moderately effective. It may also come in handy, though in most cases, the cancer is not cured. It was found that approximately 1 out of 5 patients is responding completely. Although it is not a completely curative solution, it is a valuable alternative to those patients who are unable to undergo surgery and whose conditions cannot respond to BCG.

What Is the Dosage of Valrubicin?

The recommended dose is 800 mg administered intravesically once weekly for six weeks, with the solution retained in the bladder for approximately two hours before voiding. Patients should be monitored every three months for recurrence or progression of carcinoma in situ.

What Are the Things to Inform the Doctor Before Taking the Drug?

Your doctor must be aware of:

• In case of allergy to Valrubicin or other drugs.

• Every drug, nutritional supplement, or over-the-counter remedy you use.

• In case you experience issues with your bladder, such as infection, incontinence, overactive bladder, or weak bladder walls.

• Bladder surgical history.

• In case of problems with restraining urine.

• Women are also to speak about birth control, as Valrubicin is not to be applied in pregnancy.

How Is Valrubicin Administered?

Valrubicin is not a home-use medication and must only be administered by a trained medical professional in a hospital or clinical setting.

The drug is delivered directly into the urinary bladder (intravesical administration) using a catheter, a thin, flexible tube inserted through the urethra, the channel through which urine flows.

The medication should remain in the bladder for about 2 hours after instillation to fully contact the bladder lining and be effective in treatment. This is the time when patients should refrain from urinating.

In case it is difficult or impossible to hold the medication, the healthcare provider should be notified as soon as possible.

What Precautions Should Be Taken?

Before starting Valrubicin therapy, your bladder integrity, whether there is a hole or you have a weak bladder wall, or if you have had any recent surgery in the bladder, must be adequately assessed.

If you have had recent bladder surgery, your doctor may advise you to delay treatment to reduce other unwanted effects. Similarly, you must be on effective contraception to prevent pregnancy.

What Are the Side Effects of Valrubicin?

The majority of side effects are mild and will resolve on their own, though it is also essential to inform your doctor in case you are bothered by them.

These may include:

• Bladder pain.

• Bladder spasm (a sudden tightening of the bladder that causes urgency or pain).

• Red or pink urine in the first 24 hours after the administration.

• Painful or difficult urination.

• Increased urination during the night.

• Nausea.

• Stomach pain.

• Urine leakage.

• Increased urge for urination.

Some side effects require immediate medical intervention. Contact your physician at once in case you observe:

• Blood in the urine.

• Painful urination lasts more than 24 hours.

• Pain or burning sensation while urinating.

• Low white blood cell counts.

• Fever.

• Mouth sores.

• Skin sores.

• Cough.

• Trouble breathing.

• Sore throat.

• Changes in the amount of urine.

• Inability to pass urine.

Although it is infrequent, individuals may experience allergic reactions. Signs include:

• Rash.

• Hives.

• Itching.

• Swelling of the lips or throat.

• Selling of face.

• Peeling skin.

• Wheezing.

• Trouble breathing.

• Difficulty swallowing.

• Unusual hoarseness.

• A feeling in the chest.

For Doctors:

What Are the Pharmacological Aspects of Valrubicin?

Pharmacokinetics:

Because it is administered intravesically, this medicine has easier access to bladder cancer cells. The bladder wall cells will be penetrated, allowing this drug to exert more than 90% of its cytotoxic effects on bladder cancer cells.

Systemic exposure remains minimal, but that depends on the bladder wall condition. The distribution of this medicine is basically through plasma proteins. The liver enzymes break it down into metabolites, which are also active and help eliminate cancer.

Mechanism of Action:

Valrubicin, an anthracycline, can stop the cancer cells from growing and dividing. This medicine can affect nucleic acid metabolism in several ways. Once this medicine is given, it can enter cancer cells by penetrating them.

Once it gets in, it causes chromosomal damage, and as a result, the cell division process will stop at the G2 phase. However, this medicine as such would not bind to DNA.

But it halts cell division through its metabolite molecules. These metabolites inhibit a crucial enzyme, topoisomerase II.

Pharmacodynamics:

This aspect is not significant, as this medicine is used intravesically. Hence, its effects are limited to bladder cells only, and no significant drug concentration reaches the blood to affect the body otherwise.

Contraindications

• Hypersensitivity to Valrubicin and other anthracyclines.

• Hypersensitivity to polyoxyl castor oil and other ingredients of the prescribed formulation.

• Perforated bladder mucosa.

• Active urinary tract infections.

• Minimal bladder capacity or in individuals who cannot tolerate the installation of 75 milliliters.

Administration and Dosing Considerations:

The vials should be kept warm at room temperature before each use. Check for a clear solution, and do not use the coils if any particulate matter is seen.

Then dilute 800 milligrams (20 milliliters) with about 55 milliliters of normal saline. It is recommended to use non-PVC (polyvinyl chloride) infusion sets and containers to avoid leakage of di(2-ethylhexyl phthalate) plasticizers. Moreover, this solution is not intended to be mixed with other drugs.

For intravesical instillation, a urinary catheter is inserted under aseptic conditions. Then, the bladder is drained. This is followed by the gradual instillation of 800 mg/75 mL (milliliters) of solution by gravity flow for minutes.

Then, the catheter can be removed. Ask the patient to retain the solution in the bladder for about 2 hours, then void it. Adequate hydration should eventually be considered with the treatment.

Consider temporary discontinuation or treatment delay for Grade 3 Dysgeusia and Grade 2 or Grade 3 hematuria. For local toxicities less than Grade 4 (dysuria, bladder spasm), topical anesthesia or anticholinergics can be administered before subsequent installations.

Monitor for progression and recurrence of carcinoma in situ (CIS) every 3 months. Delay treatment for at least 2 weeks after transurethral resection or fulguration.

Toxicity:

The suspected complications of overdosage of Valrubicin include certain irritable bowel symptoms.

Myelosuppression can occur if Valrubicin is unpromptedly given through systemic administration or in case of any marked systemic exposure occurring after intravesical administration.

Warnings:

Urine might be red or pink for almost a day after the treatment session with this medicine, and that is normal after this.

However, if it continues for so many days, it is concerning and needs to be checked. Also, this medicine may not be effective for everyone; only 1 in 5 people benefit, so if you're not getting results, don't continue it for long.

Couples must be warned of the fetal harm that this medicine can cause, and they must be instructed to use contraceptive measures to ensure that no pregnancy occurs. And it has to be continued even six months after the treatment.

Irritable bowel might worsen with this medicine, so it's better not to suggest it for them. Valrubicin's side effects and risks both need to be considered before suggesting it as a treatment.

Considerations To Be Noted:

Animal studies revealed that Varubicin can cause harm to a fetus, but not been substantiated through clinical trials.

Females of reproductive age should use effective birth control aids during the treatment and for a minimum of six months following the final dosage. If advising Valrubicin for a nursing mother, instruct that breastfeeding has to be on hold while on Valrubicin therapy.

Conclusion

Valrubicin therapy is a less invasive approach to save your bladder. Here, since the medicine is confined to the bladder, you will get minimal systemic effects, as the likelihood of it entering the bloodstream is lower than with systemic cancer medicine. First, your doctor must consider whether you are a perfect fit. It gives hope to those who have not benefited from regular cancer treatments.

Consult a cancer specialist to assess the available treatment options, as choosing the right medication can significantly affect outcomes

Key Takeaways:

• Valrubicin provides a chance for people with BCG-resistant bladder cancer who aren't ready for surgery, though it doesn't promise a definite cure.

• This drug differs from typical chemotherapy because it targets cancer cells and has fewer systemic effects.

• A person must carefully assess whether this therapy is the right choice for an individual patient.